Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5316810 | 0.99 | OPRM1 (0.48) | OPRM1KMT2AALDH1A1POLBLMNA | |
| SCHEMBL13278520 | 0.89 | OPRM1 (0.51) | OPRM1KMT2AALDH1A1POLBLMNA | |
| SCHEMBL16660444 | 0.86 | POLB (0.62) | OPRM1KMT2AALDH1A1POLBLMNA | |
| SCHEMBL5810393 | 0.86 | OPRM1 (0.40) | OPRM1KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL25713297 | 0.86 | POLB (0.52) | OPRM1KMT2AALDH1A1POLBLMNA | |
| SCHEMBL962133 | 0.86 | OPRM1 (0.62) | OPRM1KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL24529777 | 0.86 | OPRM1 (0.46) | OPRM1KMT2AALDH1A1POLBLMNA | |
| SCHEMBL13268808 | 0.85 | ALDH1A1 (0.65) | OPRM1KMT2AALDH1A1POLBLMNA | |
| Hydrochloric Acid SCHEMBL5810389 | 0.85 | OPRM1 (0.39) | OPRM1KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL16111685 | 0.84 | OPRM1 (0.56) | OPRM1KMT2AALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266867-B2 | Piperidinyl monocarboxylic acids as S1P1 receptor agonists | BIOPROJET (FR) | 2016-02-23 | — | — | US | disclosed |
| EP-2697219-B1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2015-03-04 | — | — | EP | disclosed |
| EP-2697219-B1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2015-03-04 | — | — | EP | disclosed |
| US-20140099316-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2014-04-10 | — | — | US | disclosed |
| WO-2012140020-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2012-10-18 | — | — | WO | disclosed |
| EP-2511275-A1 | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists | BIOPROJET (FR) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511275-A1 | Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists | BIOPROJET (FR) | 2012-10-17 | — | — | EP | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
| US-7576106-B2 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576106-B2 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2007073432-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073432-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2007044885-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044885-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR4, CCR5 | OPRM1 190/4885KMT2A 3495/4885ALDH1A1 903/4885 |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CCR1, CCR3, CCR4 | OPRM1 33/4885KMT2A 4268/4885ALDH1A1 803/4885 |
| US-20140099316-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | OPRM1 588/4885KMT2A 2768/4885ALDH1A1 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.